1-5 of 5
Suddhasatta Acharyya
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)

Claire N. Harrison, Jean-Jacques Kiladjian, MD PhD, Florian H. Heidel, MD, Alessandro M. Vannucchi, MD, Francesco Passamonti, Amjad Hayat, MBBS, MRCP, FRCPath, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, MD, Daniel B. Lipka, MD, Suddhasatta Acharyya, PhD, Prashanth Gopalakrishna, MBBS, MRCS, Susan Ide, PhD, Tracy Liu, Song Mu, PhD, Vincent Ribrag, MD
Journal: Blood
Blood (2015) 126 (23): 4060.
https://doi.org/10.1182/blood.V126.23.4060.4060
Published: 2015
Journal Articles

Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study

Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS, Miklos Egyed, MDPhD Prof., Giuliana Alimena, MD, Carlos Graux, Jamie D. Cavenagh, MD, Huda Salman, Arpad Illes, MD PhD, Pierre Fenaux, MD PhD, Daniel J. DeAngelo, Reinhard Stauder, MD MSc, Karen Yee, MD, Nancy Y Zhu, MDFRCPC, Je-Hwan Lee, MD PhD, David Valcarcel, MD PhD, Alan MacWhannell, Zita Borbenyi, MD PhD, Antje Wegener, Lucien Gazi, Suddhasatta Acharyya, PhD, Florence Binlich, Oliver G. Ottmann, MD
Journal: Blood
Blood (2015) 126 (23): 2861.
https://doi.org/10.1182/blood.V126.23.2861.2861
Published: 2015
Journal Articles

Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk Myelofibrosis

Jean-Jacques Kiladjian, MD PhD, Florian H Heidel, MD, Alessandro M. Vannucchi, MD, Vincent Ribrag, MD, Francesco Passamonti, MD, Amjad Hayat, MBBS, PhD, Eibhlin Conneally, MB, MRCP, MRCPath, PhD, Bruno Martino, MD, Thomas Kindler, Daniel B. Lipka, MD, Suddhasatta Acharyya, Prashanth Gopalakrishna, MBBS, MRCS, Susan E Ide, PhD, Sabine Loechner, Song Mu, Claire N Harrison, DM, FRCP, FRCPath
Journal: Blood
Blood (2014) 124 (21): 711.
https://doi.org/10.1182/blood.V124.21.711.711
Published: 2014
Journal Articles

A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose

Vincen t Ribrag, Claire N Harrison, DM, FRCP, FRCPath, Florian H Heidel, MD, Jean-Jacques Kiladjian, MD, PhD, Suddhasatta Acharyya, PhD, Song Mu, PhD, Tracy Liu, Denise Williams, MD, Francis J Giles, MB, MD, FRCPI, FRCPath, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD, Thomas Kindler, MD, Francesco Passamonti, MD, Alessandro M Vannucchi, MD
Journal: Blood
Blood (2013) 122 (21): 4045.
https://doi.org/10.1182/blood.V122.21.4045.4045
Published: 2013
Journal Articles

Determination of a Phase II Dose of Panobinostat in Combination with 5-Azacitidine in Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Oliver G. Ottmann, MD, PhD, Daniel J. DeAngelo, MD, PhD, Guillermo Garcia-Manero, Michael Lübbert, Anand Jillella, MD, Mikkael A. Sekeres, MD, MS, Anita Zahlten, PhD, Margaret Squier, MD, PhD, Suddhasatta Acharyya, PhD, Ivo J. Winiger, MD, Pierre Fenaux, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 459.
https://doi.org/10.1182/blood.V118.21.459.459
Published: 2011